HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FTC’s Proposed Rule On ‘Made In The USA’ Claims Could Mean Increased Civil Penalties

Executive Summary

Companies should seek legal counsel when making “Made in the USA” claims, particularly if the Federal Trade Commission’s proposed rule on the subject is adopted as drafted. Published in July, the proposed rule would enable the FTC to obtain civil penalties from violating firms “more quickly and easily," attorneys say.

You may also be interested in...



Final Rule To Enforce FTC's ‘Made In USA’ Policy Reveals Commission's Split On Limits To Authority

FTC finalizes “Made in USA” rule codifying longstanding policy that wasn’t enforced. The rule imposes fines up to $43,280 per violation, but Commissioner Christine Wilson says rule is another example of commission exceeding its authority.

Too Small A Company To Interest US Plaintiffs’ Class Action Bar? Think Again, Attorney Says

Locke Lord, LLP senior counsel Sharon Blinkoff shares perspective from her experience defending smaller cosmetics companies against US class action plaintiff demands and litigation.

FTC Shift Under Biden Administration Begins With Chairman Simons, Senior Staff Resigning

While expected following start of Biden administration, Simon’s resignation is “somewhat of a surprise” considering it will change the balance of power to the Democrats ahead of when his term would have been ended, says advertising law attorney Ivan Wasserman.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

RS150368

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel